Compare iShares Core High Dividend ETF (HDV) vs 10X Genomics Inc (TXG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
iShares Core High Dividend ETF vs 10X Genomics Inc — how do they compare? iShares Core High Dividend ETF trades at $28.71 (market cap $14.68B), while 10X Genomics Inc trades at $80.65 (market cap $10.07B). The key difference: iShares Core High Dividend ETF is the larger of the two by market cap, and 10X Genomics Inc is more actively traded (5,657,286 versus 2,925,562). Which is the better fit depends on your goals — on Pluang, investors hold iShares Core High Dividend ETF for 117 Days and 10X Genomics Inc for 91 Days on average.
| HDV | TXG | |
|---|---|---|
Market Cap | $14.68B | $10.07B |
Volume | 2,925,562 | 5,657,286 |
52-Week High | $29.93 | $97.74 |
52-Week Low | $23.64 | $11.48 |
Typical Hold Time | 117 Days | 91 Days |
Sector | — | Health |
Enterprise Value | — | $9.59B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
HDV (iShares Core High Dividend ETF) trades at $28.82, up 1.91% today, with bullish technical signals from moving averages and oscillators. The ETF recently underwent a significant sector rebalancing, reducing healthcare exposure while increasing energy, staples, and utilities, resulting in heightened concentration risk with 62% allocation to three sectors. Recent dividend payments of $0.06-$0.10 per share demonstrate consistent income generation despite the strategic shift.
The ETF's 3% yield faces scrutiny for potentially insufficient compensation given increased concentration risk. While technical momentum remains positive, fundamental concerns about sector allocation and yield adequacy warrant careful monitoring. The combination of bullish technical indicators with fundamental repositioning creates a mixed outlook requiring balanced risk assessment.
TXG trades at $77.28, up 1.55% on the day, showing resilience despite a bearish technical signal. The company's fundamentals are improving, with revenue reaching $642.82M in 2025 and net losses narrowing significantly to -$43.54M. Recent news highlights strong demand for its Atera spatial biology platform and a favorable patent verdict. However, valuation metrics like a P/S of 15.99 and EV/EBITDA of 249.22 remain elevated, reflecting high growth expectations.
The outlook is cautiously optimistic. The primary opportunity lies in the commercial success of new platforms like Atera and Sentira driving future profitability. Key risks include the high valuation requiring flawless execution, ongoing losses, and competitive pressures in the life sciences tools sector. Analyst sentiment is mixed, with a near-even split between Buy and Hold ratings and a consensus price target slightly below the current price.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About iShares Core High Dividend ETF
The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The underlying index is comprised of qualified income paying securities that are screened for superior company quality and financial health as determined by Morningstar, Inc.'s proprietary index methodology. The fund is non-diversified.
Read more on HDV →About 10X Genomics Inc
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The product portfolio of the company includes Chromium Controller, Reagent Kits, 10x Compatible Products, and Informatics Software among others. The majority of its revenue is generated from consumables.
Read more on TXG →
